KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Preferred Dividend Payments: 2018-2019

Historic Preferred Dividend Payments for Castle Biosciences (CSTL) over the last 2 years, with Sep 2019 value amounting to $289,000.

  • Castle Biosciences' Preferred Dividend Payments fell 69.55% to $289,000 in Q3 2019 from the same period last year, while for Sep 2019 it was $3.1 million, marking a year-over-year change of. This contributed to the annual value of $2.2 million for FY2019, which is 39.73% down from last year.
  • According to the latest figures from Q3 2019, Castle Biosciences' Preferred Dividend Payments is $289,000, which was down 69.22% from $939,000 recorded in Q2 2019.
  • Castle Biosciences' Preferred Dividend Payments' 5-year high stood at $949,468 during Q4 2018, with a 5-year trough of $289,000 in Q3 2019.
  • For the 2-year period, Castle Biosciences' Preferred Dividend Payments averaged around $810,665, with its median value being $933,500 (2019).
  • Over the last 5 years, Castle Biosciences' Preferred Dividend Payments had its largest YoY gain of 16.02% in 2019, and its largest YoY loss of 69.55% in 2019.
  • Over the past 2 years, Castle Biosciences' Preferred Dividend Payments (Quarterly) stood at $949,468 in 2018, then crashed by 69.55% to $289,000 in 2019.
  • Its Preferred Dividend Payments stands at $289,000 for Q3 2019, versus $939,000 for Q2 2019 and $928,000 for Q1 2019.